$450,000.00 in Sales Expected for Ocular Therapeutix Inc (OCUL) This Quarter

Brokerages expect that Ocular Therapeutix Inc (NASDAQ:OCUL) will announce $450,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Ocular Therapeutix’s earnings. The highest sales estimate is $500,000.00 and the lowest is $400,000.00. Ocular Therapeutix posted sales of $520,000.00 in the same quarter last year, which would indicate a negative year over year growth rate of 13.5%. The firm is scheduled to report its next earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that Ocular Therapeutix will report full year sales of $1.85 million for the current financial year, with estimates ranging from $1.70 million to $1.99 million. For the next fiscal year, analysts anticipate that the firm will post sales of $23.03 million, with estimates ranging from $18.15 million to $27.90 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Ocular Therapeutix.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.37). Ocular Therapeutix had a negative net margin of 2,814.72% and a negative return on equity of 143.32%. The business had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.35 million.



OCUL has been the subject of several research analyst reports. ValuEngine raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Thursday, August 9th. HC Wainwright set a $10.00 target price on shares of Ocular Therapeutix and gave the stock a “buy” rating in a research note on Friday, July 20th. Piper Jaffray Companies initiated coverage on shares of Ocular Therapeutix in a research note on Thursday, September 6th. They set an “overweight” rating for the company. Zacks Investment Research lowered shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. Finally, Cantor Fitzgerald set a $22.00 target price on shares of Ocular Therapeutix and gave the stock a “buy” rating in a research note on Tuesday, August 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $12.00.

Shares of Ocular Therapeutix stock traded down $0.12 during trading hours on Wednesday, reaching $4.74. 7,002 shares of the company’s stock were exchanged, compared to its average volume of 389,147. Ocular Therapeutix has a 1 year low of $3.30 and a 1 year high of $8.28. The firm has a market capitalization of $203.77 million, a price-to-earnings ratio of -2.11 and a beta of 1.21. The company has a quick ratio of 4.91, a current ratio of 4.92 and a debt-to-equity ratio of 0.21.

In other Ocular Therapeutix news, CEO Antony C. Mattessich purchased 20,000 shares of Ocular Therapeutix stock in a transaction dated Monday, August 20th. The shares were acquired at an average price of $5.95 per share, with a total value of $119,000.00. Following the completion of the transaction, the chief executive officer now owns 57,900 shares of the company’s stock, valued at $344,505. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Antony C. Mattessich purchased 16,900 shares of Ocular Therapeutix stock in a transaction dated Friday, August 10th. The shares were acquired at an average cost of $6.23 per share, for a total transaction of $105,287.00. Following the transaction, the insider now directly owns 37,900 shares of the company’s stock, valued at approximately $236,117. The disclosure for this purchase can be found here. Insiders have bought 49,400 shares of company stock worth $302,912 in the last three months. Corporate insiders own 15.90% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Jennison Associates LLC lifted its position in shares of Ocular Therapeutix by 1.2% during the second quarter. Jennison Associates LLC now owns 2,319,255 shares of the biopharmaceutical company’s stock worth $15,655,000 after purchasing an additional 26,503 shares in the last quarter. BlackRock Inc. lifted its position in shares of Ocular Therapeutix by 15.9% during the second quarter. BlackRock Inc. now owns 1,965,882 shares of the biopharmaceutical company’s stock worth $13,270,000 after purchasing an additional 269,270 shares in the last quarter. Opaleye Management Inc. acquired a new stake in shares of Ocular Therapeutix during the second quarter worth about $7,499,000. Deltec Asset Management LLC lifted its position in shares of Ocular Therapeutix by 16.3% during the third quarter. Deltec Asset Management LLC now owns 619,945 shares of the biopharmaceutical company’s stock worth $4,266,000 after purchasing an additional 86,959 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Ocular Therapeutix by 11.7% during the second quarter. Northern Trust Corp now owns 362,627 shares of the biopharmaceutical company’s stock worth $2,447,000 after purchasing an additional 38,101 shares in the last quarter. 56.96% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

Further Reading: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Ocular Therapeutix (OCUL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply